Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 243 Cr.
- Current Price ₹ 201
- High / Low ₹ 262 / 190
- Stock P/E 12.9
- Book Value ₹ 100
- Dividend Yield 0.00 %
- ROCE 61.5 %
- ROE 59.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 87 | 131 | 132 | 203 | |
| 80 | 120 | 111 | 171 | |
| Operating Profit | 7 | 11 | 21 | 33 |
| OPM % | 8% | 8% | 16% | 16% |
| 0 | 0 | 1 | 2 | |
| Interest | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 1 |
| Profit before tax | 7 | 11 | 20 | 33 |
| Tax % | 25% | 27% | 27% | 26% |
| 5 | 8 | 15 | 24 | |
| EPS in Rs | 40.38 | 56.45 | 107.00 | 25.55 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 64% |
| TTM: | 67% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| Last Year: | 59% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 | 12 |
| Reserves | 5 | 13 | 28 | 44 | 109 |
| 6 | 11 | 13 | 17 | 1 | |
| 12 | 12 | 12 | 16 | 15 | |
| Total Liabilities | 25 | 37 | 54 | 86 | 137 |
| 1 | 6 | 5 | 9 | 9 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 24 | 32 | 48 | 77 | 128 | |
| Total Assets | 25 | 37 | 54 | 86 | 137 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -6 | 0 | -0 | 4 | |
| -1 | -5 | -0 | -4 | |
| 7 | 5 | 0 | 3 | |
| Net Cash Flow | -0 | 0 | -0 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 80 | 62 | 87 | 82 |
| Inventory Days | 9 | 25 | 27 | 50 |
| Days Payable | 41 | 34 | 33 | 23 |
| Cash Conversion Cycle | 49 | 53 | 81 | 109 |
| Working Capital Days | 28 | 25 | 66 | 75 |
| ROCE % | 58% | 63% | 62% |
Documents
Announcements
-
Integrated Filling Financials
22h - IPO raised Rs64.48 crore on 09-07-2025; no fund deviation; RPT disclosures not applicable.
- Announcement under Regulation 30 (LODR)-Investor Presentation 24h
-
Statement On Deviation Or Variation Of Funds Under Regulation 32 Of SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations)
2d - No deviation in utilization of IPO proceeds of Rs.64.48 crore for half-year ended Sep 30, 2025.
-
Board Meeting Outcome for Outcome Of Board Meeting Of Chemkart India Limited Pursuant To Regulation 30 And Other Applicable Provisions Of The SEBI (LODR) Regulations, 2015
2d - Half-year ended Sep 30,2025: Revenue Rs10,322.56 lakh; PAT Rs1,015.26 lakh; IPO Rs6,448 lakh proceeds.
- Un-Audited Standalone And Consolidated Financial Statement For Half Year Ended On 30Th September, 2025. 2d
Annual reports
No data available.
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.